1. Anticoagulation Highlights From the American Heart Association Meeting 2017

3. Program Goals

4. Differences Between Clinical Trial Data and Real-World Evidence

5. Advantages and Disadvantages of Using Real-World Data

7. Impact of NOAC Adherence on Clinical Outcomes Among Patients With AF

8. Real-World Evidence NOAC Use in Elderly Populations

9. Outcomes of Rivaroxaban vs Warfarin in NVAF Patients ≥ 80 Years of Age

10. PIONEER AF-PCI

11. PIONEER AF-PCI: Clinically Significant Bleeding[a] and Hospitalization[b]

12. RE-DUAL PCI

13. RE-DUAL PCI ISTH Major or CRNM Bleeding

14. Danish Registry: Patients With NVAF and MI Treated with OAC and Antiplatelet Therapy

15. NOAC Use in Patients With Cancer

16. NOAC Use in Cancer VTE-Related HRU Comparison Between Cohorts

17. Hokusai VTE-Cancer, SELECT-D

18. Summary Data on NOACs

19. Summary (cont)

20. Abbreviations

21. Abbreviations (cont)